QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 0.345
-- x --
-- x --
-- - --
$ 0.30 - $ 0.95
4,681
na
284,587
$ 3.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-26-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-16-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-24-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-12-2020 03-31-2020 10-Q
19 03-24-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-13-2019 06-30-2019 10-Q
22 05-14-2019 03-31-2019 10-Q
23 03-22-2019 12-31-2018 10-K
24 11-05-2018 09-30-2018 10-Q
25 08-13-2018 06-30-2018 10-Q
26 05-14-2018 03-31-2018 10-Q
27 03-21-2018 12-31-2017 10-K
28 11-14-2017 09-30-2017 10-Q
29 08-10-2017 06-30-2017 10-Q
30 05-11-2017 03-31-2017 10-Q
31 03-30-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-12-2016 03-31-2016 10-Q
35 03-08-2016 12-31-2015 10-K
36 11-16-2015 09-30-2015 10-Q
37 08-13-2015 06-30-2015 10-Q
38 05-15-2015 03-31-2015 10-Q
39 03-30-2015 12-31-2014 10-K
40 11-14-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-panbela-therapeutics

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.

 hc-wainwright--co-reiterates-neutral-on-panbela-therapeutics

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.

 hc-wainwright--co-downgrades-panbela-therapeutics-to-neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Panbela Therapeutics (OTC:PBLA) from Buy to Neutral.

 panbela-therapeutics-q1-2024-gaap-eps-228-misses-148-estimate

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate o...

 hc-wainwright--co-maintains-buy-on-panbela-therapeutics-lowers-price-target-to-5

HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price t...

 roth-mkm-maintains-buy-on-panbela-therapeutics-maintains-25-price-target

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.

 panbela-therapeutics-q4-2023-gaap-eps-6590-misses-2434-estimate

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(65.90) per share which missed the analyst consensus estimate ...

 top-4-health-care-stocks-that-are-preparing-to-pump-this-month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 panbela-regains-nasdaq-compliance
Panbela Regains Nasdaq Compliance
02/15/2024 13:05:07

 roth-mkm-maintains-buy-on-panbela-therapeutics-adjusts-price-target-to-25

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (NASDAQ:PBLA) with a Buy, adjusts target to $25 from $500.

 whats-going-on-with-panbela-therapeutics-stock-today

Panbela Therapeutics announced acceptance of SBP-101 abstract for presentation and disclosed details of a public offering, expe...

 panbela-therapeutics-announced-abstract-for-sbp-101-accepted-for-poster-presentation-at-american-association-for-cancer-research

Poster PresentationTitle:  Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovari...

 crude-oil-down-over-1-science-37-holdings-shares-spike-higher

U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday. Th...

 why-panbela-therapeutics-shares-are-trading-lower-by-65-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of...

 dow-edges-lower-cardlytics-shares-jump

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 20 points on Monday. The Dow traded ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION